Summary of the 20th Annual MCC Multi-Center Interest Group (MMIG) - Merkel Cell Carcinoma
Post-PD1 Therapies for Refractory MCC
This meeting report summarizes the 20th Annual MCC Multi‑Center Interest Group (MMIG) presented in Denver, CO and virtual, covering clinical trial updates, post‑PD‑1 therapies, adjuvant radiotherapy considerations, and prospective studies including single‑fraction 8 Gy SFRT and ctDNA‑guided immunotherapy. Several early‑phase studies of DLL3 targeting agents, intratumoral oncolytic viruses, and antibody‑drug conjugates were highlighted, as well as data showing low local recurrence rates after margin‑negative excision and the potential for CT‑DNA to drive early treatment decisions.
Provides up‑to‑date review of systemic options beyond PD‑1/PD‑L1 inhibitors for metastatic Merkel cell carcinoma, informing clinicians on emerging agents and the limited benefit of ipilimumab + nivolumab as first‑line therapy.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy
- Repurposed pinworm medication shows ‘promise’ as treatment for Merkel cell carcinoma
- Merkel Cell Carcinoma: Epidemiology, Target, and Therapy
- The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
- Avelumab in patients with chemotherapy‑refractory metastatic Merkel cell carcinoma: a multicentre, single‑group, open‑label, phase 2 trial